Photo by nci from unsplash
One of the biggest challenges in treating acute myeloid leukemia (AML) is relapse of aggressive disease after treatment. In this issue of Cancer Cell, Boyd et al. characterize a molecularly distinct population… Click to show full abstract
One of the biggest challenges in treating acute myeloid leukemia (AML) is relapse of aggressive disease after treatment. In this issue of Cancer Cell, Boyd et al. characterize a molecularly distinct population of chemotherapy-induced transient leukemic regenerating cells (LRCs), which can be exploited to prevent AML recurrence.
Keywords:
targeting residual;
residual leukemia;
leukemia cells;
cells chemotherapy;
leukemia
Journal Title: Cancer cell
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer cell
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!